CRESCENDO BIOSCIENCE
Crescendo Bioscience, Inc. develops quantitative and objective diagnostic tools to provide rheumatologists with clinical insights to manage patients with autoimmune and inflammatory diseases. It provides diagnostic, prognostic, staging, therapy selection, and monitoring facilities to physicians. Crescendo Bioscience, Inc. was formerly known as Riley Genomics, Inc. The company was founded in 2002 and is based in South San Francisco, California.
CRESCENDO BIOSCIENCE
Industry:
Biotechnology Health Care Medical
Founded:
2002-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.crescendobio.com
Total Employee:
51+
Status:
Closed
Contact:
(800) 469-7423
Email Addresses:
[email protected]
Total Funding:
166.68 M USD
Technology used in webpage:
SPF Apple Mobile Web Clips Icon Font Awesome Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS Google Google Cloud ASP.NET
Current Advisors List
Current Employees Featured
Founder
Investors List
Mohr Davidow Ventures
Mohr Davidow Ventures investment in Series D - Crescendo Bioscience
Skyline Ventures
Skyline Ventures investment in Series D - Crescendo Bioscience
Safeguard Scientifics
Safeguard Scientifics investment in Series D - Crescendo Bioscience
Kleiner Perkins
Kleiner Perkins investment in Series D - Crescendo Bioscience
Aeris Capital
Aeris Capital investment in Series D - Crescendo Bioscience
Kleiner Perkins
Kleiner Perkins investment in Series C - Crescendo Bioscience
Mohr Davidow Ventures
Mohr Davidow Ventures investment in Series C - Crescendo Bioscience
Aeris Capital
Aeris Capital investment in Series C - Crescendo Bioscience
Kleiner Perkins
Kleiner Perkins investment in Series B - Crescendo Bioscience
Mohr Davidow Ventures
Mohr Davidow Ventures investment in Series B - Crescendo Bioscience
More informations about "Crescendo Bioscience"
About Us - Crescendo Biologics
Crescendo Biologics is focused on novel T cell enhancing therapeutics in immuno-oncology. Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, …See details»
Crescendo Biologics - Crunchbase Company Profile & Funding
Organization. Crescendo Biologics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Crescendo Biologics is engaged in …See details»
Leadership Team - Crescendo Biologics
CMO. Dr Kenji Hashimoto joins the Company with over 15 years’ experience in oncology and immuno-oncology. Prior to joining Crescendo, Kenji led the clinical development for a …See details»
Crescendo Biologics Limited | LinkedIn
Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, …See details»
Crescendo Biologics - Org Chart, Teams, Culture & Jobs - The Org
View Crescendo Biologics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Crescendo Biologics Company Profile 2024: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Crescendo Biologics. Use the PitchBook Platform to explore the full profile.See details»
Crescendo Biologics - VentureRadar
Crescendo Biologics is a drug discovery and development company in oncology based on its proprietary Humabody™ VH technology. ... Find out more about Crescendo Biologics, …See details»
Crescendo Bioscience - Crunchbase Company Profile & Funding
Crescendo Bioscience, Inc. develops quantitative and objective diagnostic tools to provide rheumatologists with clinical insights to manage patients with autoimmune and inflammatory …See details»
Myriad Genetics to Acquire Crescendo Bioscience®
SALT LAKE CITY, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has entered into a definitive agreement to acquire Crescendo …See details»
Crescendo Bioscience - PitchBook
Crescendo Bioscience General Information Description. Operator of a molecular diagnostics company focused in rheumatology. The company is focused on developing and …See details»
Kenji Hashimoto - CMO at Crescendo Biologics - The Org
Dr Kenji Hashimoto joins the Company with over 15 years’ experience in oncology and immuno-oncology. Prior to joining Crescendo, Kenji led the clinical development for a checkpoint …See details»
Crescendo Biologics Announces Prestigious New Collaboration …
Oct 20, 2021 CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell …See details»
Crescendo Biologics Expands its Ongoing Collaboration with Takeda
Dec 10, 2020 CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics, today …See details»
Our Pipeline - Crescendo Biologics
Our Pipeline – Overview. Crescendo is developing novel Humabody ® therapeutics capable of delivering safer, more durable anti-cancer responses in patients with hard-to-treat cancers. Its …See details»
Crescendo Biologics announces initiation of Phase 1 study of …
May 20, 2021 CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell …See details»
BioNTech, Crescendo Bio collaborate to develop multi-specific …
Jan 10, 2022 luismmolina/iStock via Getty Images. BioNTech (BNTX-2.6%) and Crescendo Biologics have entered a multi-target discovery collaboration to develop novel …See details»
BioNTech and Crescendo Biologics team up to develop multi …
Jan 11, 2022 The modular nature of Humabodies make them particularly suited for the development of multi-target immunotherapies. “Crescendo’s platform provides excellent …See details»
Strategic collaborations - Crescendo Biologics
Orano Med. Orano Med is a nuclear biotech company developing innovative therapies in oncology. Orano Med has developed new processes for producing lead-212 (²¹²Pb), a rare …See details»
Crescendo Bioscience Secures $56 Million in Funding to Expand ...
Sep 14, 2011 The $25 million investment by Myriad Genetics is non-dilutive capital that is structured as long term debt and is accompanied by a three-year option to acquire Crescendo …See details»